Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (843)	7/19/1999 11:18:00 PM
From: Vector1	Read Replies (2) \| Respond to of 2001

I think it is called SepraCoat and it was rejected by the FDA. It was approved in Europe. the following is from the 10K General Surgery. Genzyme Surgical Products has established a growing presence in the general surgery market through its biomaterials and endoscopic instruments. Its lead product in this market is Seprafilm(R) Bioresorbable Membrane. During the third quarter of 1996, the FDA granted approval to market Seprafilm(R) Bioresorbable Membrane for use for the reduction of the incidence and extent or adhesions in any open abdominal or pelvic surgery. Genzyme launched sales of Seprafilm(R) Bioresorbable Membrane in Europe in 1996, in Canada and Israel in 1997, and in Japan in 1998. Genzyme General is also marketing Sepracoat(TM) Coating Solution and Seprafilm(R) II Adhesion Barrier, a second generation Seprafilm(R) product designed to have increased plasticity, as adhesion prevention products in Europe.